The Drug Price Control Order (DPCO) aims to bring non-scheduled drugs under price control by changing the price setting method. A committee under DoP joint secretary had been asked in April to submit a report on amendments regarding pricing to DPCO 2013. The Indian Pharmaceutical Alliance (IPA), a grouping of leading domestic drug companies, however, believes that such an amendment would "kill competition and compromise growth" Under the existing provision, companies that launched combination or single dose drugs that might not be part of the essential list before 2013 continue to remain outside price control. Any company that wants to launch a new drug has to apply to the drug regulator, which fixes the retail price accordingly. But under the proposed provisions, if a company is launching a new drug that might be a combination of a scheduled and a non-scheduled drug, the regulator will fix the ceiling price of the drug. This means that those companies that have launched similar drugs before 2013 will automatically have to follow the ceiling price. This move will discourage manufacturers from launching new drugs, thereby reducing competition and protecting existing players. India's $15-billion generic pharma industry has witnessed a long period of slow growth as price cuts and bans on fixed-dose combination drugs as well as GST have put a halt to the double-digit expansion of a few years ago. There has also been the talk of asking doctors to prescribe drugs by generic name rather than brand name to disrupt any nexus between drug companies and doctors. However, some of the initiatives haven't worked as intended.